` AGN (Argenica Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

AGN
vs
S&P/ASX 300

Over the past 12 months, AGN has outperformed S&P/ASX 300, delivering a return of 14% compared to the S&P/ASX 300's 3% growth.

Stocks Performance
AGN vs S&P/ASX 300

Loading

Performance Gap
AGN vs S&P/ASX 300

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
AGN vs S&P/ASX 300

Loading
AGN
S&P/ASX 300
Add Stock

Competitors Performance
Argenica Therapeutics Ltd vs Peers

S&P/ASX 300
AGN
LLY
JNJ
NOVO B
ROG
Add Stock

Argenica Therapeutics Ltd
Glance View

Market Cap
82m AUD
Industry
Pharmaceuticals

Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.

AGN Intrinsic Value
HIDDEN
Show
Back to Top